Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
Thrombotic microangiopathy associated with use of interferon-beta.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Use of amiloride and multiple sclerosis: registry-based cohort studies.
Development of cladribine at Scripps for hairy cell leukemia and current results.
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Complex antibody profiling to predict clinical outcome in childhood ADS.
Gordon Research Conference on Glia Biology: Functional Interactions among Glia & Neurons
Pericytes are required for blood-brain barrier integrity during embryogenesis.
FDA approval announcement for ofatumumab
Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
[Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation.]
Novel MS Drug Offers Good Functional Outcomes
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate.
Keystone Symposium: Advances in the Knowledge and Treatment of Autoimmunity
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.

Pages